| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07198074 Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin… |
Trial sites expanded: 206 -> 211 locations |
| 2026-06-12 | NCT05765851 A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors |
overall status: "Active Not Recruiting" → "Recruiting" |
| 2026-06-12 | NCT03907475 Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid… |
date change Primary completion pushed: 2026-06-01 -> 2027-06-01 |
| 2026-06-12 | NCT03907475 Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid… |
date change Completion pushed: 2026-06-01 -> 2027-06-01 |
| 2026-06-12 | NCT06921785 Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without… |
Trial sites expanded: 217 -> 220 locations |
| 2026-06-12 | NCT05803382 Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT05803382 Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT06532032 A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With… |
Trial completed |
| 2026-06-12 | NCT05647122 First in Human Study of AZD9592 in Solid Tumors |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-12 | NCT05647122 First in Human Study of AZD9592 in Solid Tumors |
Enrollment reduced: 403 -> 167 participants |
| 2026-06-12 | NCT05647122 First in Human Study of AZD9592 in Solid Tumors |
Trial sites reduced: 51 -> 46 locations |
| 2026-06-11 | NCT07198724 ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients… |
Sponsor changed: Sarah Sammons, MD -> Kristina A. Fanucci |
| 2026-06-11 | NCT05633654 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's… |
Trial sites expanded: 339 -> 350 locations |
| 2026-06-11 | NCT06252649 Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without… |
Trial sites expanded: 286 -> 290 locations |
| 2026-06-11 | NCT06252649 Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without… |
date change Primary completion pushed: 2028-01-31 -> 2028-09-25 |
| 2026-06-11 | NCT06252649 Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without… |
date change Completion pushed: 2031-08-31 -> 2032-04-25 |
| 2026-06-11 | NCT05083481 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab… |
Trial terminated |
| 2026-06-11 | NCT05083481 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab… |
date change Primary completion moved earlier: 2026-06-30 -> 2026-05-11 |
| 2026-06-11 | NCT05083481 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab… |
date change Completion moved earlier: 2026-06-30 -> 2026-05-11 |
| 2026-06-11 | NCT07413939 RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People… |
Trial sites expanded: 4 -> 55 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07642960 Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal… | Recruiting | |
| 2026-06-10 | NCT07637851 Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer | Phase 1/2 | Not Yet Recruiting |
| 2026-06-10 | NCT07639138 Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC | Phase 2 | Recruiting |
| 2026-06-10 | NCT07639528 Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted… | Phase 2 | Not Yet Recruiting |
| 2026-06-09 | NCT07637513 Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer | Phase 3 | Not Yet Recruiting |
| 2026-06-08 | NCT07632690 QLC5508 in Participants With Metastatic Prostate Cancer | Phase 3 | Not Yet Recruiting |
| 2026-06-05 | NCT07628504 Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk… | Phase 3 | Not Yet Recruiting |
| 2026-06-05 | NCT07630077 Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or… | Phase 2 | Not Yet Recruiting |
| 2026-06-05 | NCT07630103 Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast… | Phase 2 | Not Yet Recruiting |
| 2026-06-05 | NCT07631000 A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or… | Phase 2 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05376878 | An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+… | Anatomic Stage IV Breast Cancer AJCC v8 | Recruiting |
| NCT07059494 | Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver… | Hepatocellular Carcinoma | Recruiting |
| NCT06031233 | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | Oncology | Recruiting |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or… | Advanced Biliary Tract Carcinoma | Recruiting |
| NCT07094893 | Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type… | Colorectal Cancer | Not Yet Recruiting |
| NCT04928261 | Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage… | Breast Cancer | Active, Not Recruiting |
| NCT07574047 | MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced… | Melanoma | Not Yet Recruiting |
| NCT07619235 | A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination… | Biliary Tract Cancer (BTC) | Not Yet Recruiting |
| Phase 3 | |||
| NCT04095299 | Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With… | Cancer of Rectum | Recruiting |
| NCT06899126 | Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in… | Non-small Cell Lung Cancer | Recruiting |
| NCT06644781 | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic… | Esophageal Squamous Cell Carcinoma | Recruiting |
| NCT06908304 | A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in… | Carcinoma, Non-Small -Cell Lung | Recruiting |
| NCT07315750 | A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus… | Gastric Carcinoma | Recruiting |
| NCT06830889 | A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer… | HER2-positive Breast Cancer | Recruiting |
| NCT07284134 | JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced… | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Recruiting |
| NCT07229625 | A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing… | Advanced Biliary Tract Cancer | Recruiting |
| NCT07196774 | A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in… | Early-stage or Locally Advanced HER2-positive Breast Cancer | Recruiting |
| NCT04495088 | Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With… | Rectal Cancer | Recruiting |
| NCT07389265 | Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer | Metastatic Colorectal Cancer (mCRC) | Recruiting |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in… | Metastatic HER2-positive Breast Cancer | Recruiting |
| NCT07023315 | A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for… | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Recruiting |
| NCT06767514 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With… | Non-Small Cell Lung Cancer | Recruiting |
| NCT06888817 | Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic… | Radiation Necrosis | Recruiting |
| NCT07377643 | IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in… | HER2-positive Breast Cancer | Recruiting |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for… | Gastroesophageal-junction Cancer | Recruiting |